MITF Modulates Therapeutic Resistance through EGFR Signaling

Response to targeted therapies varies significantly despite shared oncogenic mutations. Nowhere is this more apparent than in BRAF(V600E)-mutated melanomas where initial drug response can be striking and yet relapse is commonplace. Resistance to BRAF inhibitors have been attributed to the activation...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:J Invest Dermatol
Autores principales: Ji, Zhenyu, Chen, Yiyin Erin, Kumar, Raj, Taylor, Michael, Njauw, Ching-Ni Jenny, Miao, Benchun, Frederick, Dennie T., Wargo, Jennifer A., Flaherty, Keith T., Jönsson, Göran, Tsao, Hensin
Formato: Artigo
Lenguaje:Inglês
Publicado: 2015
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4466007/
https://ncbi.nlm.nih.gov/pubmed/25789707
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.105
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares